Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 8—August 2006


Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†Comments to Author 
Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Table 3

Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*

Week No history of PCP
History of PCP
n Geometric mean (95% CI) n Geometric mean (95% CI)
Baseline (0) 59 4.1 (2.8–6.0) 19 4.2 (2.0–9.0)
1–2 18 9.9 (4.6–21.5) 6 3.9 (0.5–30.8)
3–4 11 17.9 (5.9–53.6)† 6 3.0 (0.7–12.1)
5–6 13 4.4 (2.6–7.4) 4 1‡

*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 versus week 0.
‡Observed values were equal.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO